Effectiveness of platelet transfusion in dengue fever: A randomized controlled trial

Transfusion Medicine and Hemotherapy

Volumn 40, Issue 5, 2013, Pages 362-368

  Assir, Muhammad Zaman Khan ^a   Kamran, Umair ^a   Ahmad, Hafiz Ijaz ^a   Bashir, Sadia ^a   Mansoor, Hassan ^a   Anees, Saad Bin ^a   Akram, Javed ^a  

^a JINNAH HOSPITAL   (Pakistan)

Author keywords

CCI; Corrected count increment; Dengue fever; Dengue hemorrhagic fever; Platelet transfusion; Single donor apheresis platelets; Transfusion reaction

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; CORRECTED COUNT INCREMENT; DENGUE; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; POST TRANSFUSION PLATELET INCREMENT; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION REACTION; DISEASE SEVERITY; OUTCOME ASSESSMENT; RISK FACTOR; THERAPY EFFECT; THROMBOCYTE; TREATMENT RESPONSE;

EID: 84886625651     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000354837     Document Type: Article

References (19)

1. Kroeger A, Nathan M, Hombach J: World Health Organization TDR Reference Group on Dengue. Dengue. Nat Rev Microbiol 2004;2: 360-361.
2. Teixeira MG, Barreto ML: Diagnosis and management of dengue. BMJ 2009;339:b4338.
3. Halstead SB: Dengue. Lancet 2007;370: 1644-1652.
4. WHO: Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Hemorrhagic Fever. Revised and Expanded Edition. World Health Organization, Regional Office for South-East Asia, 2011. www.searo.who.int/ LinkFiles/Dengue- DHF-prevention and control-guidelines-rev.pdf.
5. Nimmannitya S: Clinical spectrum and management of dengue haemorrhagic fever. Southeast Asian J Trop Med Pub Hlth 1987;18(3): 392-397.
6. Mitrakul C, Poshyachinda M, Futrakul P, Sangkawibha N, Ahandrik S: Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg 1977;26: 975-984.
7. Mairuhu AT, Mac Gillavry MR, Setiati TE: Is clinical outcome of dengue-virus infections influenced by coagulation and fibrinolysis? A critical review of the evidence. Lancet Infect Dis 2003;3: 33-41.
8. Krishnamurti C, Kalayanarooj S, Cutting MA, Peat RA, Rothwell SW, Reid TJ, Green S, Nisalak A, Endy TP, Vaughn DW, Nimmannitya S, Innis BL: Mechanisms of hemorrhage in dengue without circulatory collapse. Am J Trop Med Hyg 2001;65: 840-847.
9. Gaydos LA, Freireich EJ, Mantel N: The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962;266: 905-909.
10. Lye DC, Lee VJ, Sun Y, Leo YS: Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection. Clin Infect Dis 2009;48: 1262-1265.
11. Lum LC, Abdel-Latif Mel-A, Goh AY, Chan PW, Lam SK: Preventive transfusion in DSS - is it necessary? J Pediatr 2003;143: 682-684.
12. Chairulfatah A, Setiabudi D, Agoes R, Colebunders R: Thrombocytopenia and platelet transfusions in dengue haemorrhagic fever and dengue shock syndrome. Dengue Bull 2003;27.
13. Payne BA, Pierre RV: Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984;59: 123-125.
14. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47: 207-214.
15. Lin CF, Wan SW, Cheng HJ, Lei HY, Lin YS: Autoimmune pathogenesis in dengue virus infection. Viral Immunol 2006;19: 127-132.
16. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, Mc- Cullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH: Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19: 1519-1538.
17. Carr JM, Kruskall MS, Kaye JA, Robinson SH: Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 1986;80: 1051-1054.
18. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337: 1861-1869.
19. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S: Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362: 600-613.